{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:03:52Z","timestamp":1794002632422,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jcyt.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:04:53Z","timestamp":1655442293000},"page":"869-878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing"],"prefix":"10.1016","volume":"24","author":[{"given":"Muna","family":"Qayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Doug","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee F.","family":"Clough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Willert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcyt.2022.05.003_bib0001","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/cells9051225","article-title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL","volume":"9","author":"Korell","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.jcyt.2022.05.003_bib0002","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/trf.15178","article-title":"Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies","volume":"59","author":"Tuazon","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0003","unstructured":"Moskop A, Talano J-A, Verneris M, Baggott C, Prabhu S, Pacenta HL, et la. Immune reconstitution and infections in the real-world use of tisagenlecleucel in pediatric and young adult acute lymphoblastic leukemia. Presented at the 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Digital Experience; February 8-12, 2021. Poster 405."},{"issue":"1","key":"10.1016\/j.jcyt.2022.05.003_bib0004","doi-asserted-by":"crossref","first-page":"e28739","DOI":"10.1002\/pbc.28739","article-title":"Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia","volume":"68","author":"Moskop","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.jcyt.2022.05.003_bib0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPH.0000000000001857","article-title":"Use of CD19-directed CAR T-cell therapy in an infant with refractory acute lymphoblastic leukemia","volume":"43","author":"Breese","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"21","key":"10.1016\/j.jcyt.2022.05.003_bib0006","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jcyt.2022.05.003_bib0007","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0008","series-title":"Presented at the 63rd American Society of Hematology Annual Meeting and Exposition","article-title":"Tisagenlecleucel leukapheresis and manufacturing outcomes in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","author":"Willert","year":"2021"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0009","series-title":"Presented at the 2022 American Society of Pediatric Hematology\/Oncology Conference","article-title":"Tisagenlecleucel leukapheresis and manufacturing outcomes in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","author":"Willert","year":"2022"},{"issue":"12","key":"10.1016\/j.jcyt.2022.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jcyt.2019.10.005","article-title":"Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture","volume":"21","author":"Tyagarajan","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136187","article-title":"Pseudo-allogeneic CAR-T therapy after allogeneic stem cell transplantation in relapsed\/refractory B-cell nhl","volume":"136","author":"Siglin","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jcyt.2022.05.003_bib0012","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.3390\/cancers13184664","article-title":"CAR-T after stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies?","volume":"13","author":"Bartolo-Ibars","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jcyt.2022.05.003_bib0013","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.jcyt.2022.05.003_bib0014","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/trf.14569","article-title":"Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma","volume":"58","author":"Ceppi","year":"2018","journal-title":"Transfusion (Paris)"},{"issue":"5","key":"10.1016\/j.jcyt.2022.05.003_bib0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2022.05.003_bib0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2022.05.003_bib0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-143336","article-title":"Factors affecting lymphocyte collection efficiency and manufactured product specification during leukapheresis for diffuse large B cell lymphoma patients treated with commercial tisagenlecleucel","volume":"136","author":"Perez Perez","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2022.05.003_bib0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.jcyt.2022.05.003_bib0019","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2022.05.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151178","article-title":"Tisagenlecleucel therapy: nursing considerations for the outpatient setting","volume":"37","author":"Cunningham","year":"2021","journal-title":"Semin Oncol Nurs"},{"issue":"6","key":"10.1016\/j.jcyt.2022.05.003_bib0021","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jca.21548","article-title":"Performance and safety of femoral central venous catheters in pediatric autologous peripheral blood stem cell collection","volume":"32","author":"Cooling","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0022","series-title":"Presented at the 23rd American Society of Gene & Cell Therapy Annual Meeting","article-title":"Leukapheresis and tisagenlecleucel manufacturing in patients less than 3 years of age with elapsed\/refractory acute lymphoblastic leukemia","author":"Eldjerou","year":"2020"},{"issue":"Supplement_1","key":"10.1016\/j.jcyt.2022.05.003_bib0023","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1182\/blood-2019-127346","article-title":"Tisagenlecleucel manufacturing feasibility in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","volume":"134","author":"Eldjerou","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2022.05.003_bib0024","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jca.21222","article-title":"Anticoagulation techniques in apheresis: from heparin to citrate and beyond","volume":"27","author":"Lee","year":"2012","journal-title":"J Clin Apher"},{"issue":"9","key":"10.1016\/j.jcyt.2022.05.003_bib0025","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0026","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.jcyt.2022.05.003_bib0027","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s40883-019-00124-3","article-title":"The challenge of variability in chimeric antigen receptor T cell manufacturing","volume":"6","author":"Fesnak","year":"2020","journal-title":"Regen Eng Transl Med"},{"issue":"2","key":"10.1016\/j.jcyt.2022.05.003_bib0028","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1073\/pnas.0237086100","article-title":"High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years","volume":"100","author":"Broxmeyer","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.jcyt.2022.05.003_bib0029","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1182\/blood-2011-01-330514","article-title":"Hematopoietic stem\/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood","volume":"117","author":"Broxmeyer","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2022.05.003_bib0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.jcyt.2022.05.003_bib0031","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0032","series-title":"Novartis Leukapheresis Reference Manual Version G2","year":"2020"},{"issue":"10","key":"10.1016\/j.jcyt.2022.05.003_bib0033","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2002-02-0657","article-title":"Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)","volume":"100","author":"Voehringer","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2022.05.003_bib0034","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11357-009-9100-9","article-title":"KLRG1\u2014more than a marker for T cell senescence","volume":"31","author":"Henson","year":"2009","journal-title":"Age"},{"issue":"320","key":"10.1016\/j.jcyt.2022.05.003_bib0035","doi-asserted-by":"crossref","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.jcyt.2022.05.003_bib0036","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0037","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2018.12.011","article-title":"G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells","volume":"116","author":"G\u0119bura","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0038","series-title":"Besponsa [Prescribing Information]","year":"2017"},{"issue":"12","key":"10.1016\/j.jcyt.2022.05.003_bib0039","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor t cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2022.05.003_bib0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00262-006-0232-9","article-title":"Imatinib impairs CD8+ t lymphocytes specifically directed against the leukemia-associated antigen RHAMM\/CD168 in vitro","volume":"56","author":"Chen","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jcyt.2022.05.003_bib0041","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2022.05.003_bib0042","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib","volume":"14","author":"Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"499","key":"10.1016\/j.jcyt.2022.05.003_bib0043","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0044","series-title":"Polivy [Prescribing Information]","year":"2020"},{"issue":"11","key":"10.1016\/j.jcyt.2022.05.003_bib0045","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","article-title":"Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab","volume":"93","author":"Garcia Munoz","year":"2014","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.jcyt.2022.05.003_bib0046","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.3109\/10428194.2015.1026818","article-title":"Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma","volume":"56","author":"Yutaka","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.jcyt.2022.05.003_bib0047","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2010.89","article-title":"Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy","volume":"24","author":"Ysebaert","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0048","series-title":"Rituxan [Prescribing Information]","year":"2021"},{"issue":"3","key":"10.1016\/j.jcyt.2022.05.003_bib0049","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/j.bbmt.2019.12.201","article-title":"Targeting of CD19 by tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro","volume":"26","author":"Horvei","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0050","series-title":"Adverse Reactions and Emergency Medical Policy. Version: 1.9. Index: C-02","author":"Merkel","year":"2021"},{"issue":"1","key":"10.1016\/j.jcyt.2022.05.003_bib0051","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0973-6247.106730","article-title":"Adverse events associated with apheresis procedures: incidence and relative frequency","volume":"7","author":"Philip","year":"2013","journal-title":"Asian J Transfus Sci"},{"issue":"5","key":"10.1016\/j.jcyt.2022.05.003_bib0052","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.transci.2018.09.008","article-title":"Risks of leukapheresis and how to manage them\u2014a non-systematic review","volume":"57","author":"Stenzinger","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"15","key":"10.1016\/j.jcyt.2022.05.003_bib0053","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood-2008-08-175323","article-title":"Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program","volume":"113","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.05.003_bib0054","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1002\/acg2.75","article-title":"Important aspects of T-cell collection by apheresis for manufacturing chimeric antigen receptor T cells","volume":"3","author":"Paroder","year":"2020","journal-title":"Adv Cell Gene Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2022.05.003_bib0055","first-page":"S328","article-title":"Leukapheresis safely and effectively yields lymphocyte populations sufficient for chronic GVHD research","volume":"21","author":"Curtis","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jcyt.2022.05.003_bib0056","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jcyt.2022.05.003_bib0057","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K\u03b4 inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jcyt.2022.05.003_bib0058","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/trf.15178","article-title":"Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies","volume":"59","author":"Tuazon","year":"2019","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.jcyt.2022.05.003_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102769","article-title":"Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients","volume":"59","author":"Hutt","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"6","key":"10.1016\/j.jcyt.2022.05.003_bib0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOH.0000000000000611","article-title":"Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector cell therapy","volume":"27","author":"Shi","year":"2020","journal-title":"Curr Opin Hematol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922006417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922006417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:47:05Z","timestamp":1761443225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324922006417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1465324922006417"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.05.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}